Unipolar Depression
Conditions
Keywords
unipolar depression, escitalopram, pindolol
Brief summary
The main purpose of this study is to determine whether the antidepressant response of escitalopram 30mg/day or escitalopram 20mg/day + pindolol, a beta blocker, is different (faster) compared to a standard dose of escitalopram 20mg/day.
Detailed description
Antidepressant drug therapy is the primary therapeutic treatment option in moderate to severe Major Depressive Disorder. However, clinically significant antidepressant response needs sustained treatment during weeks to months. Indeed, in the largest effectiveness study conducted to date (STAR\*D study) involving nearly 3000 depressed outpatients, only about one third of those who ultimately responded did so after 6 weeks of drug treatment and for most patients longer treatment periods were necessary. This delay implies prolonged suffering for the patients and their families. By its antagonist action on the serotonin 1A receptor pindolol is hypothesized to reduce the down-regulation mechanisms of antidepressants. It is therefore expected that addition of pindolol to escitalopram will shorten the therapeutic response. Clinical and preclinical data indicate that escitalopram at 30 mg/day might be more effective and perhaps be associated with a faster onset of action than 20mg. For this purpose the speed of action will be compared between three blindly randomized samples: * escitalopram 20mg per day + placebo * escitalopram 30mg per day + placebo * escitalopram 20mg per day + pindolol 15mg per day (two doses of 7.5mg during 14 days). Subjects will be followed for 6 weeks. The dose of 15mg pindolol per day (during 14 days) is based on the optimal occupancy of the serotonin 1A receptor. At inclusion all subjects will be assessed by a trained psychiatrist using the SCID I mood disorder part which is based on DSM IV criteria, and by means of the French version of the MINI. Severity of depression will be assessed using the MADRS clinician rated and self-report questionnaire, and the French version of the QIDS. Each week subjects will be assessed using the two versions of the Montgomery-Asberg Depression Rating Scale (MADRS) and the HCL-32 a self-report questionnaire assessing hypomania. It is planned to include 135 patients during the three years of the study duration resulting in 45 subjects in each group.
Interventions
DRUGescitalopram, pindolol
escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17
DRUGescitalopram
escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg
Sponsors
University Hospital, Geneva
University of Lausanne Hospitals
University Hospital, Basel, Switzerland
H. Lundbeck A/S
Markus KOSEL
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* patients aged between 18 and 65 years old * patients suffering from major depression according to DSM-IV with a MADRS score of at least 25 and not treated by an antidepressant at the time of inclusion with the exception of non-responders to antidepressant for a period of at least 6 weeks or not tolerating an ongoing antidepressant necessitating a change of the antidepressant(excluding fluoxetine and irreversible MAOI) * informed consent
Exclusion criteria
* any other Axis I disorder excluding anxiety disorder not dominating the clinical picture, nicotine abuse * non-responders to escitalopram in the past * already taking pindolol * pregnancy and breast feeding * contraindication to one of the two treatments (medical conditions, drug treatments) * significant somatic comorbidity interfering with the study procedures * high risk of suicidality * women of childbearing age not having a safe means of contraception
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MADRS score change between baseline and 2 weeks of treatment | day 14 | Differences in MADRS score changes (baseline-day 14) between treatment groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response/remission (MADRS) at 6 weeks | day 42 | % of patients with a given treatment which meet response/remssion criteria after 6 weeks of treatment, based on MADRS |
| Adverse events | See primary outcome measure | Frequence of adverse events in treatment groups |
| Correlation of drug level of pindolol and/or escitalopram and clinical outcome (primary outcome) between treatment groups | Day 10 | — |
Countries
Switzerland
Outcome results
None listed